Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01767675 · ClinicalTrials.gov registry record · Phase 2

Outcomes After Secondary Cytoreductive Surgery With or Without Carboplatin Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Followed by Systemic Combination Chemotherapy for Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

A Phase 2 study, sponsored by Memorial Sloan Kettering Cancer Center.

Completed
Registry status
Phase 2
Development phase
99
Enrollment target

NCT01767675: Completed Phase 2 study, sponsored by Memorial Sloan Kettering Cancer Center.

NCT01767675 is a Phase 2 study that has completed, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 99 participants. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01767675, a Phase 2 study, has completed, sponsored by Memorial Sloan Kettering Cancer Center.

COMPLETED
Registry status
Phase 2
Development phase
99 participants
Enrollment target

Study Summary

The purpose of this study is to see if the investigators can improve the treatment of this type of cancer. They want to find out what effects, good and/or bad, giving heated chemotherapy into the belly, known as hyperthermic intraperitoneal chemotherapy (HIPEC), has on the patient and this type of cancer. The goal of HIPEC is to expose any cancer left in the abdomen after surgery to high doses of chemotherapy. The chemotherapy is heated in the hope that this will make it easier for it to get into and kill the cancer cells. The drug used for HIPEC will be carboplatin, a Food and Drug Administration (FDA) approved drug for use in ovarian, fallopian tube or primary peritoneal cancer.

Interventions

  • PROCEDURE Secondary Cytoreductive Surgery
  • DRUG Carboplatin Hyperthermic Intraperitoneal Chemotherapy (HIPEC)
  • DRUG platinum-based systemic chemotherapy postoperatively

Trial Details

FieldValue
Enrollment Target 99 participants
Start Date 2013-01-08
Est. Completion 2025-08-26
Phase Phase 2

Sponsor

Memorial Sloan Kettering Cancer Center

1,884 total trials

What the Registry Record Tells You About NCT01767675

The ClinicalTrials.gov registry entry for NCT01767675 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 99 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 3 interventions - of which Secondary Cytoreductive Surgery is the first listed.

NCT01767675 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT01767675 about?

NCT01767675 is a clinical study titled "Outcomes After Secondary Cytoreductive Surgery With or Without Carboplatin Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Followed by Systemic Combination Chemotherapy for Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer". The purpose of this study is to see if the investigators can improve the treatment of this type of cancer. They want to find out what effects, good and/or bad, giving heated chemotherapy into the belly, known as hyperthermic intraperitoneal chemotherapy (HIPEC), has on the patient and this type of c...

What is the current status of trial NCT01767675?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 99 participants. The study started on 2013-01-08. Estimated completion is 2025-08-26.

What interventions are being tested in trial NCT01767675?

The interventions under investigation include: Secondary Cytoreductive Surgery (PROCEDURE), Carboplatin Hyperthermic Intraperitoneal Chemotherapy (HIPEC) (DRUG), platinum-based systemic chemotherapy postoperatively (DRUG).

Who is sponsoring clinical trial NCT01767675?

This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.